14442-12-7

Basic information

• Product Name: 3-PHENYL-5-ISOXAZOLECARBOXYLIC ACID
• Synonyms: ART-CHEM-BB B028629;TIMTEC-BB SBB007338;3-PHENYL-5-ISOXAZOLECARBOXYLIC ACID 97%;3-Phenylisoxazole-5-carboxylic acid 97%;5-isoxazolecarboxylic acid, 3-phenyl-;5-Carboxy-3-phenylisoxazole;3-Phenylisoxazole-5-carboxylicacid97%;AKOS B028629
• CAS NO: 14442-12-7
• Molecular Formula: C₁₀H₇NO₃
• Molecular Weight: 189.17
• Mol File: 14442-12-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 159-163 °C(lit.)
• Boiling Point: 200°C
• Flash Point: 216.7°C
• Appearance: /
• Density: 1.32g/cm³
• Vapor Pressure: 2.51E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• Solubility: soluble in Methanol
• PKA: 2.23±0.10(Predicted)
• Sensitive: Moisture & Light Sensitive
• CAS DataBase Reference: 3-PHENYL-5-ISOXAZOLECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PHENYL-5-ISOXAZOLECARBOXYLIC ACID(14442-12-7)
• EPA Substance Registry System: 3-PHENYL-5-ISOXAZOLECARBOXYLIC ACID(14442-12-7)

Safety Data

• Hazard Codes: Xi
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 14442-12-7(Hazardous Substances Data)

Usage

General Description

3-Phenyl-5-isoxazolecarboxylic acid is a chemical compound with the molecular formula C10H7NO3. It is a highly stable heterocyclic compound, containing both an isoxazole and a carboxylic acid functional group. It is commonly used as a building block in organic synthesis and medicinal chemistry, where it can be used to create various biologically active compounds. Additionally, it has been found to exhibit antimicrobial and antifungal properties, making it potentially useful as an agent for treating infections. Overall, 3-phenyl-5-isoxazolecarboxylic acid is a versatile and important chemical with potential applications in pharmaceuticals, agrochemicals, and materials science.

InChI:InChI=1/C10H7NO3/c12-10(13)9-6-8(11-14-9)7-4-2-1-3-5-7/h1-6H,(H,12,13)/p-1

Upstream product

• 13599-24-1 ethyl 3-phenylisoxazole-5-carboxylate 
• 99866-77-0 5-ethynyl-3-phenyl-isoxazole 
• 64402-51-3 phenyl 3-phenyl-5-isoxazolylmethyl ketone 
• 13599-23-0 3-phenyl-isoxazole-5-carboxylic acid isopropyl ester 
• 1821-34-7 N-chlorobenzamide 
• 698-16-8 benzohydroximoyl chloride 
• 81745-44-0 benzohydroximoyl chloride 
• 100-52-7 benzaldehyde 
• 932-90-1 Benzaldoxime 
• 932-90-1 syn-benzaldehyde oxime 
• 471-25-0 Propiolic acid 
• 55367-28-7 5-(furan-2-yl)-3-phenyl-4,5-dihydroisoxazole 
• 5910-23-6 1-furan-2-yl-3-phenyl-propane-1,3-dione 
• 2975-99-7 2-furyl phenylethynyl ketone 

Downstream Products

• 1258502-20-3 N-(2-(5-chloro-1H-indol-3-yl)ethyl)-3-phenylisoxazole-5-carboxamide 
• 1235471-85-8 4-chloro-3-methoxy-N-({1-[(3-phenyl-5-isoxazolyl)carbonyl]-4-piperidinyl}methyl)benzamide 
• 1198119-07-1 C₂₇H₂₄N₂O₄S 

Relevant articles and documents

Discovery of Farnesoid X Receptor Antagonists Based on a Library of Oleanolic Acid 3-O-Esters through Diverse Substituent Design and Molecular Docking Methods

The pentacyclic triterpene oleanolic acid (OA, 1) with known farnesoid X receptor (FXR) modulatory activity was modified at its C-3 position to find new FXR-interacting agents. A diverse substitution library of OA derivatives was constructed in silico through a 2D fingerprint similarity cluster strategy. With further docking analysis, four top-scored OA 3-O-ester derivatives were selected for synthesis. The bioassay results indicated that all four compounds 3 inhibited chenodeoxycholic acid (CDCA)-induced FXR transactivation in a concentration-dependent mode. Among them 3b and 3d are more active than the parent compound OA. A molecular simulation study was performed to attempt to explain the structure-Activity relationship (SAR) and the antagonistic action. To the best of our knowledge, this is the first report on semi-synthetic pentacyclic triterpenoids with FXR-modulatory activities.

ISOXAZOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

The invention relates to a compound of Formula (I) and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula (I) or II to a patient in need thereof: Formula (I) and Formula (II). The invention relates to the use of substituted oxazole and substituted thiazole compounds in the treatment of cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases.

Boronic acid catalysis for mild and selective [3+2] dipolar cycloadditions to unsaturated carboxylic acids

Herein, the concept of boronic acid catalysis (BAC) for the activation of unsaturated carboxylic acids is applied in several classic dipolar [3 + 2] cycloadditions involving azides, nitrile oxides, and nitrones as partners. These cycloadditions can be used to produce pharmaceutically interesting, small heterocyclic products, such as triazoles, isoxazoles, and isoxazolidines. These cycloadducts are formed directly and include a free carboxylic acid functionality that can be employed for fur-ther transformations, thereby avoiding prior masking or functionalization. In all cases, BAC provides faster reactions, under milder conditions, with much improved product yields and regioselectivities. In some instances, such as triazole formation from the reaction of azides with 2-alkynoic acids, catalysis with ort/io- nitrophenylboronic acid circumvents the undesirable product decarboxylation observed when using thermal activation. By using NMR spectroscopic studies, the boronic acid catalyst was shown to provide activation by a LUMO-lowering effect in the unsaturated carboxylic acid, likely via a monoacylated hemiboronic ester intermediate.